Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
AstraZeneca
US Army
Accenture
Cipla
Boehringer Ingelheim
US Department of Justice
Express Scripts
Johnson and Johnson

Generated: April 26, 2018

DrugPatentWatch Database Preview

VERELAN PM Drug Profile

« Back to Dashboard

When do Verelan Pm patents expire, and what generic alternatives are available?

Verelan Pm is a drug marketed by Recro Gainesville and is included in one NDA.

The generic ingredient in VERELAN PM is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
Drug patent expirations by year for VERELAN PM
Medical Subject Heading (MeSH) Categories for VERELAN PM
Synonyms for VERELAN PM
( inverted question mark)-Verapamil hydrochloride
(??)-Verapamil hydrochloride
(?)-Verapamil hydrochloride
(+-)-5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile monohydrochloride
(+-)-Verapamil hydrochloride
(+/-)-VERAPAMIL HYDROCHLORIDE
(+/-)-Verapamil hydrochloride, >=99% (titration), powder
(+/-)-Verapamil hydrochloride, pharmaceutical secondary standard; traceable to USP and PhEur
(+/-)-Verapamil, Hydrochloride
(S)-(-)-Verapamil Hydrochloride
(y)-Verapamil hydrochloride
152-11-4
152V114
2-(3,4-dimethoxyphenyl)-5-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-2-isopropylpentanenitrile hydrochloride
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-isopropyl-pentanenitrile hydrochloride
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-propan-2-yl-pentanenitrile hydrochloride
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile hydrochloride
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile;hydrochloride
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile hydrochloride
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-isopropylpentanenitrile hydrochloride
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}-2-(methy lethyl)pentanenitrile, chloride
23313-68-0
36622-29-4
38176-10-2
5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile hydrochloride
5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile monohydrochloride
5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile Hydrochloride
54236-EP2305219A1
54236-EP2308562A2
A816666
AB0018370
AC-16228
AC-8483
AC1L1Y4V
AC1Q3CE8
Akilen
AKOS005267117
AN-7969
Anpec
API0024301
Apo-Verap
ARONIS24174
Arpamyl LP
AS-16018
BBC/320
BC210130
Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, monohydrochloride
Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, monohydrochloride, (+-)-
Benzeneacetonitrile,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-, monohydrochloride
Berkatens
BG0353
BIV1326
C27H38N2O4.HCl
C27H39ClN2O4
Calan (TN)
Calan SR
Calaptin
Calaptin 240 SR
Calcan hydrochloride
Cardiabeltin
Cardiagutt
Cardibeltin
Cardioprotect
CAS-152-11-4
Caveril
CC-35585
CCG-39491
CHEMBL1280
Civicor
Civicor Retard
Coraver
Cordilox SR
Corpamil
Covera
Covera-HS
Covera-hs (TN)
CS-1685
D-365 hydrochloride
D00619
Dignover
Dilacoran HTA
DOQPXTMNIUCOSY-UHFFFAOYSA-N
DSSTox_CID_14095
DSSTox_GSID_34095
DSSTox_RID_79114
DTXSID2034095
Durasoptin
EINECS 205-800-5
Elthon
EN300-124002
EU-0101237
Flamon
FT-0603360
FT-0655647
Geangin
Harteze
Hexasoptin
Hexasoptin Retard
HMS1568M04
HMS1922J16
Hormitol
HSDB 3928
HY-A0064
I06-0615
Ikacor
Ikapress
IN1425
Inselon
Iproveratril hydrochloride
Isoptin Retard
Isoptin SR
Isoptino
Isotopin hydrochloride
Izoptin
Jenapamil
K-4825
Lekoptin
Lodixal
LP01237
LS-161199
LU 20175
Magotiron
Manidon
Manidon Retard
MFCD00055208
MLS000069485
MLS001055442
MLS002222213
MolPort-002-915-466
NCGC00024710-03
NCGC00094479-01
NCGC00094479-02
NCGC00094479-03
NCGC00094479-04
NCGC00094479-05
NCGC00258732-01
NCGC00261922-01
Novapamyl LP
Novo-Veramil
NSC 135784
NSC 272366
NSC-272366
NSC-657799
NSC-759589
NSC272366
NSC657799
NSC759589
Nu-Verap
Opera_ID_1210
OR075078
OR245357
Ormil
Pharmakon1600-02300307
Praecicor
Prestwick_440
Q-201923
Quasar
R(+)-VERAPAMIL
R853
Rapam
Robatelan
s4202
SC-18887
SCHEMBL33296
SMR000059109
SPECTRUM2300307
ST066908
ST24050346
Tox21_201180
Tox21_501237
Univex
V 4629
Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-, monohydrochloride
Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-,monohydrochloride
Vasolan (TN)
Vasomil
Vasopten
Vera-Sanorania
VERA? HYDROCHLORIDE
Verabeta
Veracaps SR
Veracor
Verahexal
Veraloc
Veramex
Veramil
Verapamil (hydrochloride)
Verapamil Acis
Verapamil AL
Verapamil Atid
Verapamil Basics
Verapamil chloridrate
Verapamil Ebewe
Verapamil HCl
Verapamil Henning
Verapamil hydrochloride
Verapamil Hydrochloride (Isoptin, Iproveratril, Calan)
Verapamil hydrochloride (JP17/USP)
Verapamil hydrochloride [USAN:JAN]
Verapamil hydrochloride [USAN:USP:JAN]
Verapamil Hydrochloride 1.0 mg/ml in Methanol (as free base)
Verapamil hydrochloride, European Pharmacopoeia (EP) Reference Standard
Verapamil hydrochloride, United States Pharmacopeia (USP) Reference Standard
Verapamil Injection
Verapamil MSD
Verapamil NM
Verapamil NM Pharma
Verapamil Nordic
Verapamil PB
Verapamil Riker
Verapamil SR
Verapamil Verla
Verapamil-AbZ
VERAPAMILHYDROCHLORIDE
Verapamyl hydrochloride
Verapin
Verapress 240 SR
Verasal
Verasifar
Veratensin
Verdilac
Verelan (TN)
Verelan SR
Veroptinstada
Verpamil
Vetrimil
Vortac
Z2210978706
ZX-AFC000544
ZX-AS004533

US Patents and Regulatory Information for VERELAN PM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-001 Nov 25, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-002 Nov 25, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-003 Nov 25, 1998 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for VERELAN PM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-003 Nov 25, 1998 ➤ Sign Up ➤ Sign Up
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-001 Nov 25, 1998 ➤ Sign Up ➤ Sign Up
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-002 Nov 25, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for VERELAN PM
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 100 mg and 200 mg ➤ Subscribe 2006-07-20
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 2006-05-19

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Citi
Accenture
McKinsey
Chinese Patent Office
Johnson and Johnson
Boehringer Ingelheim
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.